11.09% More Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Short Interest

May 16, 2018 - By Arnold Ferreira

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Corporate Logo

It was showed an increase on Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s shorted shares with 11.09%. FINRA issued in May ANTH’s total 2.14M shorted shares. The up change of 11.09% from 1.92 million shares was reported. With Average volume 770,900, ANTH’s former position will take 3 days to recover.

ANTH is touching $0.3026 during the last trading session, after decreased 2.83%.Anthera Pharmaceuticals, Inc. has volume of 270,082 shares. Since May 16, 2017 ANTH has declined 90.50% and is downtrending. ANTH underperformed the S&P 500 by 102.05%.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.The firm is valued at $7.08 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy.Last it reported negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

In total 3 analysts cover Anthera Pharmaceuticals (NASDAQ:ANTH). “Buy” rating has 1, “Sell” are 1, while 1 are “Hold”. 33% are bullish. 5 are the (NASDAQ:ANTH)’s analyst reports since January 22, 2018 according to StockzIntelligence Inc. On Monday, March 12 the firm has “Sell” rating given by Piper Jaffray. On Tuesday, March 6 the firm earned “Hold” rating by Jefferies. On Monday, January 22 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, February 13 the stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) earned “Hold” rating by Jefferies.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: